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REVIEW CURRENTOPINION What are the dominant cytokines in early
rheumatoid arthritis?1040-8711 Copyright  2017 The ALaura A. Ridgley, Amy E. Anderson, and Arthur G. PrattPurpose of review
Rheumatoid arthritis is a systemic disease of evolving immune dysregulation that culminates in joint
destruction and disability. The principle by which pro-inflammatory cytokines may be therapeutically
targeted to abrogate disease is well established, but has yet to translate into reliable cures for patients.
Emerging insights into cytokine-mediated pathobiology during rheumatoid arthritis development are
reviewed, and their implications for future treatment strategies considered.
Recent findings
Accumulating data highlight cytokine perturbations before the clinical onset of rheumatoid arthritis. Some of
these have now been linked to the arthritogenic activation of autoantibodies and associated pain and bone
destruction in affected joints. These observations suggest cytokines may trigger the transition from systemic
immunity to arthritis. Cytokine exposure could furthermore ‘prime’ synovial stromal cells to perpetuate a
dominant pro-inflammatory environment. By facilitating cross-talk between infiltrating immune cells and even
sustaining ectopic lymphoid structure development in some cases, cytokine interplay ultimately underpins
the failure of arthritis to resolve.
Summary
Successful therapeutic stratification will depend upon an increasingly sophisticated appreciation of how
dominant players amongst cytokine networks vary across time and anatomical space during incipient
rheumatoid arthritis. The prize of sustained remission for all patients justifies the considerable effort required
to achieve this understanding.
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Rheumatoid arthritis is a systemic inflammatory
disease that primarily affects the synovial joints,
and for which there is no known cure. Its heteroge-
neity, instantly recognizable to clinicians in the
variability of its clinical presentation, is multilay-
ered, confounding a unified description of patho-
genesis. In particular, the concept that distinct
subtypes of the syndrome are delineated by the
presence or absence of circulating antibodies to
citrullinated peptides (ACPAs) has gained traction
recently [1,2]. In ACPA ‘seropositive’ disease, ele-
gant epidemiological and translational work con-
verges on a stepwise model for disease development
[1] in which cigarette smoke exposure, other envi-
ronmental effects and the microbiome act as princi-
pal risk factors for autoantibody development long
before symptom onset [3–5]. Genetically deter-
mined amino acid sequences in the MHC binding
groove of antigen presenting cells then gainuthor(s). Published by Wolters Kluweinfluence in driving accelerated autoimmunity
and the transition to arthritis in at-risk individuals
[1,6]. Mechanisms behind the development of sero-
negative rheumatoid arthritis remain far less well
understood, its heritability and association with
smoking both apparently modest by comparison,
but a recent familial aggregation study suggests ther Health, Inc. www.co-rheumatology.com
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KEY POINTS
 An increasingly sophisticated appreciation of how
‘dominant’ players within cytokine hierarchies may vary
over time, across tissue boundaries and between
individuals during incipient rheumatoid arthritis is
now emerging
 Abnormal levels of pro-inflammatory and Th2-related
cytokines are found in the circulation prior to
symptom onset.
 New roles for cytokines of the IL-23/Th17 axis, type I
interferons and IL-8 have been suggested in the
progression of ACPA-positive arthralgia.
 An ‘imprinted’ pathological phenotype of stromal cells
in the joint appears to respond aberrantly to cytokine
stimuli at a critical phase in rheumatoid
arthritis development.
 Pro-inflammatory mediators such as TNF, IL-6 and GM-
CSF drive persistent synovitis and the systemic
complications of rheumatoid arthritis.
Immunopathogenesis and treatment of autoimmune diseasesaetiological overlap between these serotypes may be
more important than yet fully appreciated [7]. Run-
ning through this complex backdrop of disease ini-
tiation, and orchestrating the common phenotype
of persistent synovial hyperplasia, immune cell
infiltration and joint destruction that ensues, the
fundamental importance of cytokines in rheuma-
toid arthritis pathogenesis is long established
(Table 1).
Cytokines are typically secreted by leukocytes to
exert paracrine or autocrine effects, thereby regulat-
ing such diverse functions as cellular differentiation,
activation, migration and survival. Exhibiting plei-
otropy individually and synergy or redundancy in
concert, the sensitivity of their combinatorial net-
works to perturbation is exquisite, and their indi-
vidual potential for exploitation as therapeutic
targets well recognized. Blockade of signalling by
pro-inflammatory cytokines, such as tumour necro-
sis factor (TNF) and interleukin-6 (IL-6), using
monoclonal antibodies has revolutionized out-
comes for patients with severe rheumatoid arthritis
but, in common with all currently available bio-
logics, these drugs remain subject to a ‘therapeutic
ceiling’, with true remission unattainable for the
majority. Replicating even this degree of success
in the clinic has proved difficult in clinical trials
of alternative agents, for example blocking IL-1b, IL-
17 and the IL-12/23 family in rheumatoid arthritis –
despite their attractiveness as targets [8–10]. Rather
than being interpreted as evidence that these cyto-
kines are pathogenetically unimportant, such set-
backs should prompt amore nuanced critique of our2 www.co-rheumatology.comcurrent therapeutic approach. An increasingly
sophisticated appreciation of how ‘dominant’ play-
ers within cytokine hierarchies may vary over time,
across tissue boundaries and between individuals
during incipient rheumatoid arthritis is now emerg-
ing (Fig. 1). Developing and harnessing this under-
standing, perhaps guided by judicious sampling of
blood or tissue at an individual patient level tomore
rationally map therapeutic strategies to disease
endotypes, should one day pay dividends in the
clinic. The present review will show how recent
insights into the role of cytokines in the earliest
stages of rheumatoid arthritis have advanced this
endeavour.CYTOKINES AS COORDINATORS OF PRE-
CLINICAL RHEUMATOID ARTHRITIS
Genes encoding functional components of the
immune system are enriched within loci associated
with the development and natural history of rheu-
matoid arthritis; protein products pathogenetically
implicated include cytokines themselves [IL-2, IL-
21, G-CSF and granulocyte macrophage-colony
stimulating factor (GM-CSF)], their receptor compo-
nents [for IL-6, IL-20, interferon (IFN)-g and IL-2]
and elements of their downstream signalling
machinery (e.g. TYK2, STAT4 and TNFAIP3). The
range of epigenetic and other mechanisms via
which such variants might disrupt cytokine homeo-
stasis to confer disease risk is only beginning to be
understood, together with an appreciation that they
will best be dissected at a cellular level in relevant
disease contexts [11,12]. This becomes pertinent
when considering measurable alterations in a num-
ber of circulating cytokines that have, with some
consistency, been observed prior to symptom onset
amongst those who subsequently develop rheuma-
toid arthritis compared with healthy individuals.
These include increased pro-inflammatory exam-
ples (TNF, IL-6, IL-1b and/or IL-1RA, GM-CSF) as
well as IL-4, IL-12, IL-17 and the eosinophil chemo-
tactic chemokine, eotaxin (Table 1). Against a fac-
ultative genetic background, such mediators may
variously arise from the paucicellular joint itself,
bone marrow or elsewhere in the periphery, but
their presence reinforces the likely contribution of
cytokines to systemic and general immune dysregu-
lation prior to overt synovitis. In a recent study
interrogating serum analyte profiles of ACPA sero-
positive patients with joint pain (arthralgia), the
discriminatory value of the Th2-specific cytokine
IL-5 for rheumatoid arthritis progression was
highlighted [13
&
]. Together with the elevated circu-
lating IL-4 and eotaxinmentioned above, these data
recall much earlier observations of transient Th2Volume 29  Number 00  Month 2017
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Table 1. Overview of cytokines with established and emerging roles in early rheumatoid arthritis pathogenesis
Cytokine
Typical cellular
source(s) Cellular target(s) [and effect(s)]
Proposed role(s) in
rheumatoid arthritis Targeting strategy/ies
TNF Monocytes/
macrophages.
SFs (pro-inflammatory cytokine
production)
Osteoclasts (differentiation,
activation)
Endothelium (neovascularization)
- Lymphocytes (Treg inhibition)
Pro-inflammatory
Bone erosion
Systemic (?fatigue)
Anti-TNF (infliximaba,
adalimumaba,
golimumaba,
cerolizumaba), TNFR
(etanercepta).
IL-6 Monocytes/
macrophages,
stroma/SFs
SFs (activation, proliferation)
Macrophage (osteoclast
differentiation)
T cells (proliferation, survival,
Th17 differentiation)
B cells (survival, antibody
production).
Hepatocytes (acute phase
reactants)
Pro-inflammatory
Systemic (atherosclerosis,
impaired lipid
metabolism, anaemia)
Anti-IL-6R (tocilizumaba,
sarilumab), anti-IL-6
(sirukumab)
IL-1a/b Monocytes/
macrophages, DCs
Osteoclasts (activation)
T cells (Th17 differentiation)
Endothelium (vasodilation)
Autocrine (pro-inflammatory)
Pro-inflammatory
(contributory rather than
dominant role)
IL-1RA (anakinra), anti-IL-1b
(canakinumab).
IL-17A/F Th17 cells, neutrophils,
ILCs, iNKT cells.
SFs (proliferation, pro-
inflammatory cytokine
production, including IL-6)
- Chondrocytes (metalloproteinase
induction)
Myeloid cells/neutrophils
(chemotaxis)
Endothelium (neovascularization)
Pro-inflammatory
(?contributory versus
dominant role depending
on disease subset)
Anti-IL-17A (secukinumab),
anti-IL-17RA
(brodalumab).
IL-23 Macrophages, DCs Th17 cells (development,
maintenance and expansion;
IL-21/IL-22 induction)
Th17 responses Anti-p40 (common subunit
of IL-23/12;
ustekinumab), anti-IL-23
(guselkumab)
IL-21 Th17 cells, Th2 cells,
NK cells, Tfh cells.
B-cell maturation, plasma cell
development/antibody
production
?Role in arthritogenic
autoantibody
glycosylation (Ref [16])
Anti-IL-21 in development
IL-12 Macrophages, DCs Th1 cells (differentiation,
autocrine)
?Cell-mediated immune
resposes, Th17 plasticity.
Anti-p40 (common subunit
of IL-23/12;
ustekinumab)
GM-CSF Monocytes/
macrophages,
lymphocytes, stroma/
SFs
Myeloid cells (differentiation/
proliferation)
Macrophages (pro-inflammatory
phenotype)
DCs (activation)
Pro-inflammatory, ?Pain Anti-GM-CSF-Ra
(mavrilimumab)
Th2 cytokines Th2 cells, mast cells Various Awaits clarification
[13&,14,15]
Strategy to be determined.
Type I interferons Plasmacytoid DCs CD8þ T cells and NK cells
(cytotoxicity)
Th1 polarization
B cells (differentiation;
IgG class-switching)
?pathogenesis of
seropositive disease [16]
Anti-IFNa (sifalimumab)
IL-8 (CXCL8) Macrophages, epi/
endothelial cells.
Osteoclasts (?response
to autoantibodies)
Neutrophils, leukocytes
(chemotaxis)
Osteoclasts (activation, including
autocrine)
Leukocyte chemotaxis
?Bone erosion/pain in
‘pre-RA’ [19&&]
CXCR1/2 inhibitor
(reparixin)
Typical cellular sources and effects in target cells are listed, and broadly accepted roles in rheumatoid arthritis pathogenesis are summarised, along with
available/potential therapeutic targeting strategies (exemplar originator agents named).
aOnly asterisked agents are currently licensed for use in rheumatoid arthritis). Less established roles indicated by ‘?’ GM-CSF, granulocyte macrophage-colony
stimulating factor; DC, dendritic cell; ILC, innate lymphoid cell; NK, natural killer; SF, synovial fibroblast.
Dominant cytokines in early rheumatoid arthritis Ridgley et al.
1040-8711 Copyright  2017 The Author(s). Published by Wolters Kluwer Health, Inc. www.co-rheumatology.com 3
CE: Alpana; BOR/300206; Total nos of Pages: 8;
BOR 300206
FIGURE 1. The hierarchical dominance of cytokines during rheumatoid arthritis development is dynamic. Recent insights
permit a speculative depiction of how individual cytokines may exhibit distinct and evolving patterns of relative importance,
even during the earliest phases of ACPA-seropositive rheumatoid arthritis. Whilst pro-inflammatory cytokines are clearly
important drivers of seronegative disease, a paucity of equivalent data for this subset currently precludes a similarly granular
representation of this or other, as yet undefined, rheumatoid arthritis ‘pathotypes’.
Immunopathogenesis and treatment of autoimmune diseasescytokine profiles in synovial fluid of early seroposi-
tive synovitis patients who progressed to rheuma-
toid arthritis [14]. Th2 effector responses protect
against inflammatory arthritis in certain contexts
[15], and the extent to which such observations
reflect ‘failed regulation’ or merely emphasize the
role of humoral responses during preclinical rheu-
matoid arthritis remains to be clarified (Table 1).
The functional diversity of cytokines found in
the circulation of individuals at risk of rheumatoid
arthritis may be simplest to rationalize by viewing
serum merely as a conduit between distant tissue
sites, each harbouring an immunologically discrete
niche; in acknowledgment of this it was proposed
that measuring circulating mediators en masse to
derive a summary ‘cytokine score’ for disease pre-
diction might be their most practical application
[16]. Nonetheless, examples of how specific cyto-
kines actively shape antibody-mediated autoimmu-
nity in the run-up to clinically manifest rheumatoid
arthritis are now emerging. In the case of the IL-23-
Th17 axis their propensity to do so appears greater
during this ‘prearticular’ phase than after synovitis
has developed (Fig. 1). Hence, recent data from
mouse models of autoimmune arthritis show that
IL-23-activated Th17 cells can, via IL-21 and IL-22,
‘programme’ germinal centre plasmablasts and
plasma cells to alter the Fc glycosylation profile of
secreted IgG autoantibodies [17
&&
]. Reduced termi-
nal glycan sialylation at the asparagine-297 position4 www.co-rheumatology.comthereby augments autoantibody affinity for osteo-
clast Fc receptors, impacting their propensity to
localize to the joint and mediate bone loss [18].
Critically, these changes in autoantibody glycosyla-
tion directly mirror those seen to occur in circulat-
ing ACPAs of seropositive patients as their arthritis
develops [17
&&
]. Recent experiments also support a
nonredundant role for IL-8 in ACPA-mediated oste-
oclast activation as a mechanism of bone loss, and
even arthralgia, prior to arthritis development
[19
&&
,20
&
]. Here it was shown that peptidyl arginine
deiminase enzymes necessary for osteoclast differ-
entiation had, as a result of their citrullinating
activity, a secondary effect of generating additional
targets for circulating ACPA within the joint; IL-8
was specifically produced by these cells in response
to ACPA, feeding an autocrine loop that resulted in
bone loss [19
&&
] and (in mice) pain-like behaviour
[20
&
]. Considered together these data are exciting as
they point to a hitherto elusive model to explain
how systemic autoimmune propensity manifests as
joint-specific diseases; its confirmation is now
eagerly awaited.
Type I interferons including the prototype IFNa,
produced mainly by plasmacytoid dendritic cells,
may provide a further example of cytokine-medi-
ated autoantibody modulation. These factors are
known to promote a number of functions linked
to autoimmune pathology including B-cell differen-
tiation and IgG class-switching. Up-regulation ofVolume 29  Number 00  Month 2017
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BOR 300206
Dominant cytokines in early rheumatoid arthritis Ridgley et al.their target gene expression in whole blood (inter-
feron gene signature, IGS), used as a surrogate of
circulating cytokine levels, has been shown to pre-
dict IgG development in at-risk, ACPAþ individuals,
as reflected predominately by its presence in poly-
morphonuclear granulocytes [21
&&
], and IGS ele-
ments were recently shown to correlate with
ACPA titres in a Mexican population [22].
Studying the preclinical phase of seronegative
rheumatoid arthritis poses a unique and important
challenge now beginning to be addressed [23
&
]. Of
interest, patients with this subgroup of disease typi-
cally describe a shorter symptom duration when
they present with arthritis, but with evidence for
more prominent IL-6-mediated lymphocyte activa-
tion in the periphery, compared with their seropos-
itive counterparts [24,25], consistent with a more
‘explosive’, pro-inflammatory component to the
natural history of seronegative disease (Fig. 1).
The knowledge that adaptive immune activation
may be facilitated by pro-inflammatory cytokines
in the absence of ongoing antigenic stimulus [26]
suggests alternative mechanisms of sustained
immune dysregulation that warrant further study
in this subgroup.CYTOKINES IN THE TRANSITION TO
CHRONICITY
The pathological hallmarks of synovitis in rheuma-
toid arthritis include the proliferation of resident
synovial fibroblasts, new blood vessel formation and
the recruitment of awide range of leukocytes includ-
ing B and T lymphocytes, monocytes/macrophages
and mast cells; in turn this leads to synovial hyper-
trophy and the invasion of cartilage and bone by
activated inflammatory tissue. Cytokines are funda-
mental orchestrators of the development and main-
tenance of this lesion. Amongst them, TNF appears
to hold a position of hierarchical dominance during
the inflammatory disease phase, promoting the acti-
vation of osteoclasts, chondrocytes, vascular endo-
thelium and fibroblasts, and so directly mediating
synovial hypertrophy and damage whilst in turn up-
regulating the expression of other locally abundant
pro-inflammatory cytokines. These include mem-
bers of the IL-1 family, IL-6 and GM-CSF, the latter
two of which clearly possess nonredundant func-
tions, respectively in T-cell activation and the dif-
ferentiation of inflammatory macrophages and
dendritic cells. Furthermore, IL-6 and TNF exert
potent systemic effects that help drive some of
the co-morbidities seen in rheumatoid arthritis,
including altered cholesterol metabolism, athero-
sclerosis and even mood disturbance [27
&
]. Finally,
in relation to adaptive immune dysregulation, these1040-8711 Copyright  2017 The Author(s). Published by Wolters Kluwetwo cytokines were recently shown to induce the
secretion of soluble programmed cell death-1 (sPD-
1) by CD4þ T cells, competitively compromising the
normal PD-1-mediated regulation of these cells’
activation in inflammatory arthritis patients [28
&
].
The broad inflammatory features of rheumatoid
synovitis are well described [27
&
], but an emergent
literature has now set ‘early synovitis’ apart as a
distinct, transitional pathological phase in rheuma-
toid arthritis development, during which cytokine
cross-talk between cells of the stroma, endothelium
and the immune system may uniquely effect the
failure of inflammation to resolve within the joint.
Central to this concept is an appreciation that syno-
vial fibroblasts, far from functioning merely as inert
‘joint scaffolding’, instead actively direct cellular
interactions according to an epigenetically
imprinted phenotype that is potentially more vul-
nerable to the cumulative effects of inflammation
than stromal cells located elsewhere [29]. Building
on this insight, Filer et al. recently demonstrated
that an immune-protective effect exerted by TNF-
exposed synovial fibroblasts from recent-onset
arthritis patients in whom synovitis spontaneously
resolves – whereby lymphocyte adhesion to endo-
thelial cells in co-culture is prevented – was lost
amongst synovial fibroblasts derived instead from
patients with recent-onset rheumatoid arthritis, in
whom synovitis persists [30
&&
]. The phenomenon
appeared to be partly mediated by IL-6 which,
although abundant in both ‘resolving’ and ‘persis-
tent’ synovitis, mediated divergent effects during
this circumscribed disease phase. On the other
hand, only synovial fibroblasts from patients with
advanced rheumatoid arthritis promoted lympho-
cyte adhesion even in the absence of TNF [30
&&
].
These data illustrate the importance of considering
cytokine effects in the context of disease phase and
diagnostic category, andmay have consequences for
the optimal therapeutic timing of cytokine blockade
(Fig. 1). As with the preclinical disease phase, the
autoantibody status should also be considered. For
example, in patients with untreated early rheuma-
toid arthritis high circulating levels of IL-20 and IL-
24 discriminate seropositive individuals and predict
bony erosion – a property lost after treatment initi-
ation; these cytokines appear to be produced by
monocytes activated by immune complexes, and
in turn mediate osteoclast activation [31
&
].
Aside from the largely pro-inflammatory moie-
ties discussed above, recent investigations into a
number of ‘regulatory’ cytokines that shed light
on means by which immune homeostasis might
be restored during rheumatoid arthritis develop-
ment are also considered. For example, the observa-
tion that spontaneous resolution of synovitis in ar Health, Inc. www.co-rheumatology.com 5
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Immunopathogenesis and treatment of autoimmune diseasesmouse model is dependent on IL-9 raised the
intriguing possibility that this cytokine could also
regulate human RA persistence: an enrichment of
IL-9-producing type 2 innate lymphoid cells (ILC-
2s) was indeed present in the circulation and syno-
vium of patients with active rheumatoid arthritis
compared with those on effective treatment and
controls [32
&&
]. Tertiary lymphoid organs (TLOs)
that closely resemble lymphoid follicles (with segre-
gated T- and B-cell zones, follicular dendritic cell
networks and a supporting stroma) are observed in
approximately 40% of patient with rheumatoid
arthritis synovium, where they support local auto-
antibody responses and may be a marker of adverse
prognosis. It was recently shown that IL-27 inhibits
TLO development via the inhibition of podoplanin-
expressing Th17 cells [33]. Any therapeutic gains in
the light of these insights remain some way off, but
they offer a rich field for future research.CYTOKINE-TARGETED THERAPY:
LESSONS AND FUTURE DIRECTIONS
Experience gained from the use of targeted therapies
may teach usmuch about rheumatoid arthritis path-
ogenesis – including the hierarchical dominance of
individual cytokines at its various phases. The value
of achieving rapid and broad suppression of pro-
inflammatory pathways during the earliest phase of
arthritis by blocking TNF or IL-6-mediated signal-
ling has been demonstrated, for example leading to
sustained remission in about a third of patients
[34,35]. Amongst patients with rheumatoid arthritis
who fail to respond to ‘traditional’ nonbiological
DMARDs these pathways clearly remain important
drivers of disease for many, and GM-CSF blockade
has now joined the above strategies as a rapidly
effective treatment modality in this setting [36].
The efficacy of small molecular inhibitors of these
cytokines’ downstream signalling machinery (the
Janus kinase family) further supports their impor-
tance in perpetuating the inflammatory joint dis-
ease. By contrast, unsuccessful therapeutic targeting
of other pro-inflammatory cytokines, despite their
evident participation in pathogenesis, likely reflects
functional redundancy during the disease phase at
which clinical trials have thus far been undertaken.
In the case of IL-1 this is true in both early and
established rheumatoid arthritis, but attempts to
block the IL-23/17 axis have thus far tended to be
limited to patient groups with established disease
[8,9]. Conceivably, based on recent insights
described above, inhibitors of IL-23, p40 (the com-
mon subunit of IL-23 and IL-12) and IL-17A, may be
more rationally deployed in seropositive individuals
before clinically overt arthritis develops – in which6 www.co-rheumatology.comcontext the role of Th17 cells could be more pivotal
[17
&&
]. Here, the potential role of agents that block
IL-8 signalling (such as the CXCR1/2-inhibitor rep-
arixin) or IFN-a (e.g. sifalimumab) has become the
subject of similar conjecture [37].
The preponderance of ACPA and/or rheumatoid
factor seropositive patients with rheumatoid arthri-
tis amongst populations studied in most of the
clinical trials alluded to here is notable. Where it
is available, accumulating data identifies seronega-
tive rheumatoid arthritis as subject to relatively
unfavourable treatment responses, irrespective of
the targeted cytokine. Perhaps this is unsurprising
given the aetiological distinction of this subgroup,
but it highlights persistent unmet needs: not only in
pathophysiological understanding, but also in our
ability to map therapeutic response to measurable
markers of the heterogeneous disease process at an
individual patient level. Pretreatment levels of cir-
culating cytokines themselves have so far proved to
be of little value for this purpose, and the ability to
measure their effects at a cellular level and/or within
synovial tissue holds promise for stratified treat-
ment approaches [38
&
].CONCLUSION
Cytokines leave their footprint at all stages of the
natural history of rheumatoid arthritis. Their signal-
ling pathways are represented amongst genes
encoded at disease risk loci; they regulate the immu-
nological ‘prodrome’ that precedes clinically mani-
fest arthritis – including autoantibody pathogenicity
and joint pain; they mediate (and are mediated by)
stromal dysregulation within the joint at the earliest
stages of synovitis; and they define and perpetuate
the chronic inflammation that ensues.Harnessing an
understandingof howmembers of this diverse family
of molecules variously dominate at each disease
phase across disease subgroups should yield more
rational and effective treatment strategies.Acknowledgements
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